NOVO NORDISK

The UK government has awarded £650,000 to launch the Scotland CardioMetabolic Impact Study (SCoMIS), a groundbreaking research initiative targeting 3,000-5,000 participants from Scotland's most deprived communities to evaluate real-world impact of GLP-1 weight-loss medicines.

Pfizer received early U.S. Federal Trade Commission antitrust clearance for its proposed $7.3 billion acquisition of Metsera, more than a week ahead of the original November 7 deadline.

Eli Lilly's tirzepatide franchise, including Zepbound and Mounjaro, generated $10.1 billion in Q3 2024, overtaking Merck's Keytruda as the world's best-selling drug for the first time.

Ventyx Biosciences' experimental oral therapy VTX3232 demonstrated an 80% reduction in hsCRP inflammation markers within one week in a 175-patient Phase 2 trial targeting cardiovascular disease risk.

Eli Lilly has signed an agreement with Cipla to market its blockbuster weight-loss drug tirzepatide under the brand name Yurpeak in India, expanding access beyond Lilly's established presence.

Roche's shares fell 2.8% after third-quarter sales of eye disease drug Vabysmo reached 996 million Swiss francs, missing analyst expectations for the second consecutive quarter.

WeightWatchers announced a strategic partnership with Amazon Pharmacy to deliver GLP-1 obesity treatments, addressing access challenges particularly in rural areas where patients previously struggled to find medications at local pharmacies.

California becomes the first state to sell its own brand of generic insulin through the CalRx program, with five-pack insulin pens available for $55 starting January 1, 2025.

Novo Nordisk announced an asset purchase and license agreement to acquire exclusive global rights to zaltenibart from Omeros Corporation for up to $2.1 billion, including $340 million in upfront and near-term milestone payments.

Novo Nordisk is shutting down its entire cell therapy division and laying off nearly all 250 employees as part of CEO Mike Doustdar's strategic restructuring.